Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Using Santyl on Diabetic Foot Ulcers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Healthpoint
ClinicalTrials.gov Identifier:
NCT01408277
First received: August 2, 2011
Last updated: June 30, 2014
Last verified: June 2014
  Purpose

Subjects enrolled in this study will either use Santyl daily or follow standard care procedures for up to 6 weeks for their diabetic foot wound. After 6 weeks of treatment, the subjects will continue into the follow-up phase for an additional 6 weeks. Study doctors will look at the wound in the office each week (up to 12 weeks) to see if the wound is healing. Depending on a number of factors at each office visit, the study doctors may also use a procedure called sharp debridement to remove dead skin from the wound.

This study will test the hypothesis that daily treatment of diabetic foot wounds with Santyl will result in more rapid healing, healthier wounds, and fewer required sharp debridements over the study period than for diabetic foot wounds treated in other ways.


Condition Intervention Phase
Diabetic Foot Ulcers
Diabetic Foot Wounds
Biological: Santyl
Procedure: Control
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Comparison of Collagenase Santyl® Ointment Used Adjunctively to Sharp Surgical Debridement and Sharp Surgical Debridement in the Care of Diabetic Foot Wounds

Resource links provided by NLM:


Further study details as provided by Healthpoint:

Primary Outcome Measures:
  • Mean Percent Change in Wound Area [ Time Frame: 6 and 12 weeks ] [ Designated as safety issue: No ]
    Wound area was measured using the ARANZ Silhouette digital wound imaging and measurement device. The average percent (%) of change from baseline of the target wound area at the end of the 6-week treatment period and the end of the entire 12-week study period respectively, was calculated using a two-way ANCOVA model.


Enrollment: 55
Study Start Date: August 2011
Study Completion Date: March 2013
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Santyl
2mm Santyl applied once daily.
Biological: Santyl
2 mm Santyl applied once daily
Active Comparator: Control
Standard Care
Procedure: Control
Standard Care
Other Name: Standard Care

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

  • Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
  • Subjects 18 years of age or older. Subjects may be of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
  • A target ulcer which is 0.5 cm2 - 10 cm2 inclusive (as measured at the Screening Visit) with a duration ≥ 30 days (documented in the patient's history or by patient report of onset) which requires sharp surgical debridement.
  • Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.7 and ≤ 1.1. If the ABI is greater than 1.1, then a toe pressure of > 40 mmHg OR a TcPO2 ≥ 40 mmHg must be present. Either toe pressure or TcPO2 is also acceptable as a stand-alone measurement, but if both are obtained, each must meet its respective cutoff.
  • Alternatively, a Doppler waveform consistent with adequate flow to the region of the foot with the target ulcer (biphasic or triphasic waveforms) is acceptable.
  • A target ulcer that is not infected based on clinical assessment.
  • Willing and able to make all required study visits.
  • Able to follow instructions and perform the dressing changes at home or have a caregiver who can perform the dressing changes according to the protocol.
  • Willing to use an appropriate off-loading device whenever necessary to keep weight off of any foot ulcers.
  • History of diabetes mellitus (Type 1 or 2) requiring insulin or oral hypoglycemic medications to control blood glucose levels.
  • CBC and blood chemistry values as follows:

    • Serum albumin ≥ 2.0 g/dL
    • Pre-albumin levels of ≥ 15 mg/dL
    • Alkaline phosphatase ≤ 500 U/L
    • Alanine aminotransferase (ALT) ≤ 200 U/L
    • Aspartate aminotransferase (AST) ≤ 175 U/L
    • Serum total bilirubin ≤ 3.0 mg/dL
    • Serum BUN < 75 mg/dL
    • Serum creatinine ≤ 4.5 mg/dL
    • HbA1c ≤ 12%
    • Hemoglobin (Hgb) > 8.0 g/dL
    • WBC > 2.0 x 109/L
    • Absolute neutrophil count > 1.0 x 109/L
    • Platelet count > 50 x 109/L

EXCLUSION CRITERIA

  • Contraindications or hypersensitivity to the use of the study medications or their components.
  • Target ulcer does not require debridement.
  • Uncontrolled bleeding disorder.
  • Cellulitis of the target wound, lymphangitic streaking, deep tissue abscess, gangrene, or infection of muscle, tendon, joint or bone.
  • Infection with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, azotemia).
  • Any of the following:

    • Target ulcer tunneling
    • Target ulcer requires hyperbaric or negative pressure therapy per the investigator's medical judgment
    • Target ulcer is on the heel and cannot be offloaded
    • Target ulcer is over a Charcot deformity which cannot be offloaded
  • NOTE: A heel ulcer or an ulcer over a Charcot is not excluded unless effective offloading is not possible.
  • Current, ongoing osteomyelitis of the target foot as determined by medical history.
  • Participation in another investigational clinical study within thirty (30) days of the Screening Visit.
  • A target ulcer which involves underlying tissues (i.e., fat, fascia, tendon, muscle, bone).
  • A target ulcer on a non-neuropathic foot (neuropathic defined as inability to perceive 10 grams pressure using a Semmes-Weinstein 5.07 or equivalent monofilament in the periwound area).
  • NOTE: Monofilament test result must be documented.
  • Diagnosis of chronic granulomatous disease, leukocyte adhesion defects, or severe neutropenia.
  • Current treatment (at the time of the Screening Visit) with any of the following:

    • Systemic corticosteroids
    • Immunosuppressive agents
    • Chemotherapeutic agents
    • Antiviral agents
    • Platelet-derived growth factor (e.g., Regranex)
    • Living skin equivalent (e.g., Apligraf)
    • Dermal substitute (e.g., Dermagraft, Integra, etc.)
    • Systemic antibiotic therapy or topical antibiotic treatment of the target ulcer
  • Radiation therapy to the target lower extremity within 30 days prior to screening The Medical Monitor and/or Investigator may declare any subject ineligible for a valid medical reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01408277

Locations
United States, Arizona
Associated Foot and Ankle Specialists
Phoenix, Arizona, United States, 85015
Aung Foothealth Clinics
Tucson, Arizona, United States, 85710
United States, Michigan
Foot Healthcare Associates, PC
Southfield, Michigan, United States, 48076
United States, New Jersey
Overlook Hospital Wound Care Center
Summit, New Jersey, United States, 07901
United States, Texas
UNTHSC Fort Worth
Fort Worth, Texas, United States, 76107
Endeavor Clinical Trials
San Antonio, Texas, United States, 78229
Robert Wunderlich
San Antonio, Texas, United States, 78212
Sponsors and Collaborators
Healthpoint
Investigators
Study Chair: Herbert B Slade, MD Healthpoint
  More Information

No publications provided

Responsible Party: Healthpoint
ClinicalTrials.gov Identifier: NCT01408277     History of Changes
Other Study ID Numbers: 017-101-09-030
Study First Received: August 2, 2011
Results First Received: April 2, 2014
Last Updated: June 30, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Healthpoint:
Diabetic Foot Ulcers
Diabetic Foot Wounds

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Ulcer
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Diabetic Neuropathies
Endocrine System Diseases
Foot Diseases
Leg Ulcer
Pathologic Processes
Skin Diseases
Skin Ulcer
Vascular Diseases

ClinicalTrials.gov processed this record on November 20, 2014